Trial · NCT00003782
Adverse events192
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 192
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 126 | 1,748 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Docetaxel | 22 | 1,748 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Docetaxel + Cyclophosphamide | 33 | 1,745 | |
| other | Diarrhea | Gastrointestinal disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 78 | 1,748 | |
| other | Diarrhea | Gastrointestinal disorders | Doxorubicin + Docetaxel | 66 | 1,748 | |
| other | Diarrhea | Gastrointestinal disorders | Doxorubicin + Docetaxel + Cyclophosphamide | 111 | 1,745 | |
| other | Fatigue | General disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 212 | 1,748 | |
| other | Fatigue | General disorders | Doxorubicin + Docetaxel | 135 | 1,748 | |
| other | Fatigue | General disorders | Doxorubicin + Docetaxel + Cyclophosphamide | 167 | 1,745 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 383 | 1,748 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Doxorubicin + Docetaxel | 223 | 1,748 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Doxorubicin + Docetaxel + Cyclophosphamide | 275 | 1,745 | |
| other | Infections and infestations - Other, specify | Infections and infestations | Doxorubicin + Cyclophosphamide, Then Docetaxel | 200 | 1,748 | |
| other | Infections and infestations - Other, specify | Infections and infestations | Doxorubicin + Docetaxel | 144 | 1,748 | |
| other | Infections and infestations - Other, specify | Infections and infestations | Doxorubicin + Docetaxel + Cyclophosphamide | 137 | 1,745 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 148 | 1,748 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Docetaxel | 29 | 1,748 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Docetaxel + Cyclophosphamide | 35 | 1,745 | |
| other | Nausea | Gastrointestinal disorders | Doxorubicin + Cyclophosphamide, Then Docetaxel | 162 | 1,748 | |
| other | Nausea | Gastrointestinal disorders | Doxorubicin + Docetaxel | 127 | 1,748 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00003782/events